Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Afinitor Approved for Pancreatic NET in Europe: Novartis
September 9, 2011
- Takeda to Invest ¥5 Bil. on Electric Power Facility
September 9, 2011
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
- Eplerenone significantly Reduces Cardiovascular Death in High-Risk CHF Patients: Pfizer
September 7, 2011
- MTPC to Reorganize Its Subsidiary
September 7, 2011
- ASKA to Initiate Transparency GL Project on Full Scale in October
September 7, 2011
- Tarceva Approved for 1st-line in NSCLC: Roche
September 6, 2011
- Ogasawara to Become President, Ogawa to Step Down: RDKK
September 6, 2011
- Chugai Starts US-Japan PI Trials of Multiple In- Licenced Compounds from Roche
September 6, 2011
- Janssen Adds Precautions for CONCERTA for Administering to Patients Over 18
September 5, 2011
- Eisai Decides to Discontinue Development of Pariet Extended-Release Preparation
September 5, 2011
- Otsuka to Launch TS-1 in Europe in 2nd Quarter of 2012
September 5, 2011
- NDA for Lurasidone Accepted in Canada: DSP
September 5, 2011
- Large-scale Users Should Accept “Unit Price-based, By-product Deals”: Mr Bessho of JPWA
September 5, 2011
- Over 10% of Pharmacists Switched to Generic Actos in Just 1 Week: Nextit
September 5, 2011
- CSD Report Highlights Growing Importance of Biopharmaceutical Market in 2010
September 5, 2011
- Sanwa Kagaku Licenses Anagliptin to Kowa in China, Taiwan
September 5, 2011
- MSD Launches Gardasil for Prevention of Cervical Cancer
September 5, 2011
- Takeda Begins M&A Talks with 2 Indian Companies: Local Paper
September 5, 2011
- Eisai’s, DSP’s Growth Scenario Becoming More Realistic: Tachibana Securities
September 5, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…